Supernus logo

Supernus

SUPN | NASDAQ
Chart Builder DCF Calculator
$28.83
-$0.89 (-2.99%)
At close: Nov 16, 2026, 4:00 PM ET
$28.83
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.99%

Rating

Updated: Nov 17, 2026
85.5
Fundamentals Excellent
Market Sentiment Bullish
Moat Narrow
Sector Rank #1/6 (Top 17%)

Key Statistics

Market Data

Market Cap $5.99B
1D Range
28.40 29.61
52W Range
26.16 43.05

Valuation (TTM)

PE 8.05
PB -99.81
EV/EBITDA 10.89

Valuation (NTM)

Forward PE 9.33
Forward PEG 0.25
Price Target $47.00
Loading financial charts...

Profile

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans op...

Sector Healthcare
Employees 827
IPO Date Apr 30, 2012
Fiscal Year January - December

Latest News

Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

6 days ago · globenewswire.com

Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

8 days ago · benzinga.com

This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More

13 days ago · 247wallst.com

Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More
Why Indivior Pharmaceuticals Stock Topped the Market Today

14 days ago · fool.com

Why Indivior Pharmaceuticals Stock Topped the Market Today
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

18 days ago · seekingalpha.com

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

18 days ago · zacks.com

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals Q3 Earnings Call Highlights

18 days ago · marketbeat.com

Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript

18 days ago · benzinga.com

Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Supernus Announces Third Quarter 2026 Financial Results

18 days ago · globenewswire.com

Supernus Announces Third Quarter 2026 Financial Results
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600

19 days ago · prnewswire.com

Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600

Earnings

Latest Earnings
Oct 29, 2026
EPS
$1.32
Beat +24.53%
REV
$356M
Beat +8.09%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$47.00
Upside
+63.02%
Buy (3)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.